Clinical trial
Tricaprilin in Mild to Moderate Alzheimer's Disease
NCT00142805 · Cerecin, Industry · Completed
Key facts
| NCT number | NCT00142805 |
|---|---|
| Title | Tricaprilin in Mild to Moderate Alzheimer's Disease |
| Official title | Safety, Tolerability and Efficacy Study of Tricaprilin (AC-1202) Administered for Ninety Days in Subjects With Probable Alzheimer's Disease of Mild to Moderate Severity |
| Lead sponsor | Cerecin, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug, Other |
| Interventions | Tricaprilin, Placebo |
| Enrollment | 152 |
| Start date | Nov 4, 2004 |
| Primary completion | Jun 29, 2006 |
| Completion | Jan 7, 2007 |
| First posted | Sep 2, 2005 |
| Last update posted | Sep 21, 2020 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: